1887

Abstract

A prospective study was performed to evaluate the correlation between the proposed standard of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST) (document 7.1) and the commercial system Etest for determining the MICs of flucytosine, amphotericin B, fluconazole, itraconazole and voriconazole for a collection of 100 clinical and environmental isolates of . The agreements among Etest MICs within ±2 log dilutions of AFST-EUCAST standard MICs were greater for flucytosine, fluconazole and voriconazole (76, 78 and 88 %, respectively) than for amphotericin B (5 %), the lowest agreement, and itraconazole (67 %). Overall, the correlation coefficients were statistically significant (<0.05), and it is suggested that the Etest and AFST-EUCAST method are reliable alternatives and present good correlation for all drugs evaluated except amphotericin B. However, the observed differences related to MICs for susceptible, susceptible dose dependent and resistant strains between the methods suggest that it will be necessary to carry out further studies, including assessment of interlaboratory agreement and correlation of MICs by different methods with response.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46789-0
2006-12-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/12/1693.html?itemId=/content/journal/jmm/10.1099/jmm.0.46789-0&mimeType=html&fmt=ahah

References

  1. Abdel Salam, H. A. ( 2005; ). In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs. Mycoses 48, 327–32.[CrossRef]
    [Google Scholar]
  2. Aller, A. I., Martin-Mazuelos, E., Lozano, F., Gomez-Mateos, J., Steele-Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F. J. & Espinel-Ingroff, A. ( 2000; ). Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 44, 1544–1548.[CrossRef]
    [Google Scholar]
  3. Andes, D. ( 2003; ). In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47, 1179–1186.[CrossRef]
    [Google Scholar]
  4. Andes, D., Marcillo, K., Stamstad, T. & Conklin, R. ( 2003; ). In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47, 3165–3169.[CrossRef]
    [Google Scholar]
  5. Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing ( 2002; ). Method for Determination of Minimal Inhibitory Concentration (MIC) by Broth Dilution of Fermentative Yeast, discussion document E.Dis7.1. Taufkirchen: European Society of Clinical Microbiology and Infectious Diseases.
  6. Berg, J., Clancy, C. J. & Nguyen, M. H. ( 1998; ). The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 26, 186–187.
    [Google Scholar]
  7. Brandt, M. E., Pfaller, M. A., Hajjeh, R. A., Hamill, R. J., Pappas, P. G., Reingold, A. L., Rimland, D. & Warnock, D. W. for the Cryptococcal Disease Active Surveillance Group ( 2001; ). Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 45, 3065–3069.[CrossRef]
    [Google Scholar]
  8. Brass, C., Shainhouse, J. Z. & Stevens, D. A. ( 1979; ). Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother 15, 763–768.[CrossRef]
    [Google Scholar]
  9. Casadevall, A. & Perfect, J. R. ( 1998; ). Cryptococcus neoformans, 1st edn. Washington, DC: American Society for Microbiology.
  10. Chryssanthou, E., Gronfors, C. & Khanna, N. ( 1997; ). Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole. Mycoses 40, 423–427.[CrossRef]
    [Google Scholar]
  11. Clinical and Laboratory Standards Institute ( 2002; ). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, 2nd edn, M27-A2. Wayne, PA: Clinical and Laboratory Standards Institute.
  12. Clinical and Laboratory Standards Institute ( 2005; ). Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpreative Breakpoints, M27-S2. Wayne, PA: Clinical and Laboratory Standards Institute.
  13. Colombo, A. L., Barchiesi, F., McGough, D. A. & Rinaldi, M. G. ( 1995; ). Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 33, 535–540.
    [Google Scholar]
  14. Cuenca-Estrella, M., Moore, C. B., Barchiesi, F. & 12 other authors ( 2003; ). Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 9, 467–474.[CrossRef]
    [Google Scholar]
  15. Espinel-Ingroff, A. ( 1998; ). In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36, 198–202.
    [Google Scholar]
  16. Espinell-Ingroff, A., Pfaller, M., Erwin, M. E. & Jones, R. N. ( 1996; ). Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeast to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 34, 848–852.
    [Google Scholar]
  17. Espinel-Ingroff, A., Barchiesi, F., Cuenca-Estrella, M., Pfaller, M. A., Rinaldi, M., Rodriguez-Tudela, J. L. & Verweij, P. E. ( 2005; ). International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43, 3884–3889.[CrossRef]
    [Google Scholar]
  18. Ghannoun, M. A., Ibrahim, A. S., Fu, Y., Shafiq, M. C., Edwards, J. E. & Criddle, R. S. ( 1992; ). Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 30, 2881–2886.
    [Google Scholar]
  19. Groll, A. H. & Kolve, H. ( 2004; ). Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 23, 256–270.[CrossRef]
    [Google Scholar]
  20. Hitchcock, C. A., Andrews, R. J., Lewis, B. G. H. & Troke, P. F. ( 1995; ). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract F75, p. 126. Washington, DC: American Society for Microbiology.
  21. Hoban, D. J., Zhanel, G. G. & Karlowsky, J. A. ( 1999; ). In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 43, 1463–1464.
    [Google Scholar]
  22. Johnson, L. B. & Kauffman, C. A. ( 2003; ). Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36, 630–637.[CrossRef]
    [Google Scholar]
  23. Lozano-Chiu, M., Paetznick, V. L., Ghannoum, M. A. & Rex, J. H. ( 1998; ). Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performance of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 36, 2817–2822.
    [Google Scholar]
  24. McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, R., Jr & Rinaldi, M. G. ( 1997; ). In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 41, 1832–1834.
    [Google Scholar]
  25. Nguyen, M. H. & Yu, C. Y. ( 1998; ). In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 42, 471–472.
    [Google Scholar]
  26. Odds, F. C. ( 1980; ). Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother 6, 749–761.[CrossRef]
    [Google Scholar]
  27. Perfect, J. R., Marr, K. A., Walsh, T. J. & 8 other authors ( 2003; ). Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36, 1122–1131.[CrossRef]
    [Google Scholar]
  28. Perkins, A., Gomes-Lopez, A., Mellado, E., Rodrigues-Tudela, J. L. & Cuenca-Estrella, M. ( 2005; ). Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56, 1144–1147.[CrossRef]
    [Google Scholar]
  29. Petraitiene, R., Petraitis, V., Groll, A. H. & 7 other authors ( 2001; ). Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 45, 857–869.[CrossRef]
    [Google Scholar]
  30. Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K. & Ghannoum, M. A. ( 1999; ). In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 43, 169–171.[CrossRef]
    [Google Scholar]
  31. Pfaller, M. A., Messer, S. A., Houston, A., Mills, K., Bolmström, A. & Jones, R. N. ( 2000; ). Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol 38, 3715–3717.
    [Google Scholar]
  32. Pfaller, M. A., Walsh, T. J., Chaturvedi, V. & 7 other authors ( 2001; ). Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14, 643–658.[CrossRef]
    [Google Scholar]
  33. Randhawa, H. S., Kowshik, T. & Khan, Z. U. ( 2003; ). Decayed wood of Syzygium cumini and Ficus religiosa living trees in Delhi/ New Delhi metropolitan area as natural habitat of Cryptococcus neoformans. Med Mycol 41, 199–209.[CrossRef]
    [Google Scholar]
  34. Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G. & Patterson, T. F. ( 1996; ). Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 174, 821–827.[CrossRef]
    [Google Scholar]
  35. Rex, J. H., Pfaller, M. A., Walsh, T. J. & 8 other authors ( 2001; ). Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14, 643–658.[CrossRef]
    [Google Scholar]
  36. Saag, M. S., Graybill, R. J., Larsen, R. A., Papaas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D. & Dismukes, W. E. ( 2000; ). Practice guidelines for the management of cryptococcal diseases. Clin Infect Dis 30, 710–718.[CrossRef]
    [Google Scholar]
  37. Schwarz, P., Dromer, F., Lortholary, O. & Dannaoui, E. ( 2006; ). Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 50, 113–120.[CrossRef]
    [Google Scholar]
  38. Vandenbossche, I., Vaneechoutte, M., Vandevenne, M., De Baere, T. & Verschraegen, G. ( 2002; ). Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory. J Clin Microbiol 40, 918–921.[CrossRef]
    [Google Scholar]
  39. Van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A. & Nosanchuk, J. D. ( 2004; ). Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 48, 2014–2020.[CrossRef]
    [Google Scholar]
  40. Warnock, D. W., Johnson, E. M. & Rogers, T. R. ( 1998; ). Multicentre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 42, 321–331.[CrossRef]
    [Google Scholar]
  41. Yildiran, S. T., Fothergill, A. W., Sutton, D. A. & Rinaldi, M. G. ( 2002; ). In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 45, 378–383.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46789-0
Loading
/content/journal/jmm/10.1099/jmm.0.46789-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error